Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19172738 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Brummer T, et al. (2008) Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J 27, 2305-16 19172738
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EGF Gab2 (human) augment treatment-induced increase Gab2 S210A/T391A single or double mutations

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EGF Gab2 (human) augment treatment-induced increase Gab2 S210A/T391A single or double mutations

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey

S133-p - Gab2 (human)
Orthologous residues
Gab2 (human): S133‑p, Gab2 (mouse): S135‑p, Gab2 (rat): S135‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S140-p - Gab2 (human)
Orthologous residues
Gab2 (human): S140‑p, Gab2 (mouse): S142‑p, Gab2 (rat): S142‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S141-p - Gab2 (human)
Orthologous residues
Gab2 (human): S141‑p, Gab2 (mouse): S143‑p, Gab2 (rat): S143‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S148-p - Gab2 (human)
Orthologous residues
Gab2 (human): S148‑p, Gab2 (mouse): S150‑p, Gab2 (rat): S150‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S149-p - Gab2 (human)
Orthologous residues
Gab2 (human): S149‑p, Gab2 (mouse): , Gab2 (rat):
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S159-p - Gab2 (human)
Orthologous residues
Gab2 (human): S159‑p, Gab2 (mouse): S160‑p, Gab2 (rat): S160‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S164-p - Gab2 (human)
Orthologous residues
Gab2 (human): S164‑p, Gab2 (mouse): S165‑p, Gab2 (rat): S165‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human

S210-p - Gab2 (human)
Orthologous residues
Gab2 (human): S210‑p, Gab2 (mouse): S211‑p, Gab2 (rat): S211‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
wortmannin EGF inhibit treatment-induced increase
LY294002 EGF inhibit treatment-induced increase
Akt-I-1,2 EGF inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
rapamycin EGF no effect upon treatment-induced increase
U0126 EGF no effect upon treatment-induced increase
Go 6976 EGF no effect upon treatment-induced increase
Go 6850 EGF no effect upon treatment-induced increase
KN-62 EGF no effect upon treatment-induced increase
Y27632 EGF no effect upon treatment-induced increase
mPKI EGF no effect upon treatment-induced increase
PIK3CA (human) increase activated
insulin increase
Downstream Regulation
 Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation, phosphorylation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
EGFR (human) Disrupts molecular association, regulation co-immunoprecipitation
Grb2 (human) Disrupts molecular association, regulation co-immunoprecipitation
Shc1 (human) Disrupts molecular association, regulation co-immunoprecipitation
14-3-3 beta (human) Induces molecular association, regulation co-immunoprecipitation

S218-p - Gab2 (human)
Orthologous residues
Gab2 (human): S218‑p, Gab2 (mouse): , Gab2 (rat):
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human

S223-p - Gab2 (human)
Orthologous residues
Gab2 (human): S223‑p, Gab2 (mouse): S220‑p, Gab2 (rat): S220‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S264-p - Gab2 (human)
Orthologous residues
Gab2 (human): S264‑p, Gab2 (mouse): S261‑p, Gab2 (rat): S261‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

T278-p - Gab2 (human)
Orthologous residues
Gab2 (human): T278‑p, Gab2 (mouse): T275‑p, Gab2 (rat): T275‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human

S281-p - Gab2 (human)
Orthologous residues
Gab2 (human): S281‑p, Gab2 (mouse): S278‑p, Gab2 (rat): S278‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

T287-p - Gab2 (human)
Orthologous residues
Gab2 (human): T287‑p, Gab2 (mouse): T284‑p, Gab2 (rat): T284‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

Y293-p - Gab2 (human)
Orthologous residues
Gab2 (human): Y293‑p, Gab2 (mouse): Y290‑p, Gab2 (rat): Y290‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

T331-p - Gab2 (human)
Orthologous residues
Gab2 (human): T331‑p, Gab2 (mouse): T328‑p, Gab2 (rat): T328‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

T385-p - Gab2 (human)
Orthologous residues
Gab2 (human): T385‑p, Gab2 (mouse): T382‑p, Gab2 (rat): T382‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human

T391-p - Gab2 (human)
Orthologous residues
Gab2 (human): T391‑p, Gab2 (mouse): T388‑p, Gab2 (rat): T388‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
wortmannin EGF inhibit treatment-induced increase
LY294002 EGF inhibit treatment-induced increase
Akt-I-1,2 EGF inhibit treatment-induced increase
H-89 EGF inhibit treatment-induced increase
rapamycin EGF no effect upon treatment-induced increase
U0126 EGF no effect upon treatment-induced increase
Go 6976 EGF no effect upon treatment-induced increase
Go 6850 EGF no effect upon treatment-induced increase
KN-62 EGF no effect upon treatment-induced increase
Y27632 EGF no effect upon treatment-induced increase
mPKI EGF no effect upon treatment-induced increase
PIK3CA (human) increase activated
insulin increase
Downstream Regulation
 Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation, phosphorylation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Shc1 (human) Disrupts molecular association, regulation co-immunoprecipitation
EGFR (human) Disrupts molecular association, regulation co-immunoprecipitation
14-3-3 beta (human) Induces molecular association, regulation co-immunoprecipitation
Grb2 (human) Disrupts molecular association, regulation co-immunoprecipitation

S405-p - Gab2 (human)
Orthologous residues
Gab2 (human): S405‑p, Gab2 (mouse): S402‑p, Gab2 (rat): S402‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human

S480-p - Gab2 (human)
Orthologous residues
Gab2 (human): S480‑p, Gab2 (mouse): S469‑p, Gab2 (rat): G469‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human

S543-p - Gab2 (human)
Orthologous residues
Gab2 (human): S543‑p, Gab2 (mouse): S532‑p, Gab2 (rat): S532‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S622-p - Gab2 (human)
Orthologous residues
Gab2 (human): S622‑p, Gab2 (mouse): G611‑p, Gab2 (rat): G611‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S623-p - Gab2 (human)
Orthologous residues
Gab2 (human): S623‑p, Gab2 (mouse): S612‑p, Gab2 (rat): S612‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

T412-p - p70S6K (human)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  COS (fibroblast), MCF-10A (breast cell) [Gab2 (human), transfection]
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
wortmannin EGF inhibit treatment-induced increase
rapamycin EGF inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.